Jayson Rieger - 05 Jun 2026 Form 4 Insider Report for Verrica Pharmaceuticals Inc. (VRCA)

Reporting relationship: CEO and President, Director
Issuer ticker: VRCA
Reported as of: 05 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 09 Jun 2026, 16:15:14 UTC
Prior SEC filing: 25 Nov 2025
Next SEC filing: 18 Aug 2026
Source filing: View source filing
Reporting owner signature: /s/ Jayson Rieger

Key filing fact

Jayson Rieger filed Form 4 for Verrica Pharmaceuticals Inc. (VRCA) on 09 Jun 2026.

Key facts

This page summarizes Jayson Rieger's Form 4 filing for Verrica Pharmaceuticals Inc. (VRCA).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 09 Jun 2026, 16:15.

Change

Previous filing in this sequence was filed on 25 Nov 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002043558 Primary reporting owner

Rieger Jayson

Relationship: CEO and President, Director
Address: C/O VERRICA PHARMACEUTICALS INC., 44 W. GAY ST., SUITE 400, WEST CHESTER
Signature: /s/ Jayson Rieger
Signature date: 09 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

VRCA transaction Derivative

Employee Stock Option (right to buy)

Award

Transaction value
Shares: +512,269
Change %
Price: $0.000000^*
Shares after: 512,269
Date: 05 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 512,269
Exercise price: $8.21
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The option grant was approved by a committee of the Issuer's board of directors on December 23, 2025, subject to shareholder approval of an amendment to the Issuer's 2018 Equity Incentive Plan under which the option was granted. The Issuer's shareholders approved the amendment on June 5, 2026.

Footnote F2

50% of the total shares subject to the option shall vest on the date that the closing sales price per share of the Issuer's Common Stock as reported on The Nasdaq Capital Market equals at least $15.00, and 50% of the total shares subject to the option shall vest on the date that the closing sales price per share of the Issuer's Common Stock as reported on The Nasdaq Capital Market equals at least $25.00, subject to the Reporting Person's continuous service through each such vesting date.